TL;DR: ⚪ Null overall, promising subgroup — acetaminophen didn't improve organ-support-free days broadly, but a prespecified high-cell-free-hemoglobin subgroup showed the strongest signal — phase 3 warranted.
1. Publication
- Title: Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial
- Acronym: ASTER
- Year & Journal: JAMA, published May 19, 2024 (332(5):390-400)
- Citation: Ware LB, Files DC, Fowler A, et al; NHLBI PETAL Network. JAMA. 2024;332(5):390-400. doi:10.1001/jama.2024.8772
2. Context & Rationale
Background: Acetaminophen is a potent, specific hemoprotein reductant that blocks cell-free hemoglobin (CFH)-induced oxidation of lipids and other substrates. CFH is elevated in most septic patients and independently associated with organ dysfunction (ARDS, AKI) and death. A prior small trial (ACROSS, 2014, n=40) suggested improved biomarkers and kidney function.
Research Question/Hypothesis: In critically ill adults with sepsis and respiratory or circulatory organ dysfunction, does IV acetaminophen increase the number of days alive and free of organ support to day 28, compared with placebo?
3. Design & Methods
- Study Type: Phase 2b, randomized, placebo-controlled trial (NHLBI PETAL Network)
- Setting & Centers: 40 US academic hospitals; October 2021–April 2023
- Population: Adults with sepsis and respiratory or circulatory organ dysfunction
- Intervention: IV acetaminophen every 6h for 5 days
- Comparator: Placebo, same schedule
- Randomization: 447-488 patients (sources vary slightly)
- Statistical Power & Follow-Up: Primary: days alive and free of organ support to day 28. Prespecified subgroup: patients with cell-free hemoglobin above a threshold.
4. Key Results
Outcome | Acetaminophen | Placebo | Notes |
Days alive and free of organ support to day 28 (primary) | Not significantly increased overall | — | Primary endpoint not met in the full population |
High-CFH subgroup (prespecified) | Greatest benefit | — | Less assisted ventilation needed; slight, non-significant mortality decrease |
Mortality (overall) | No significant difference | — | — |
5. Internal Validity Assessment
Phase 2b, randomized, placebo-controlled, adequately sized (~447-488 patient) trial with a prespecified biomarker-defined subgroup analysis. Overall: Moderate — negative primary result in the overall population, but the CFH-high subgroup signal is prespecified (not purely post-hoc), lending some credibility as a hypothesis for phase 3 testing; as a phase 2b trial it was not designed/powered for a definitive mortality endpoint.
6. External Validity Assessment
US, 40-center academic hospital population with sepsis and organ dysfunction — broadly representative of the target population, though the informative subgroup (high CFH) requires additional biomarker testing not routinely available.
7. Strengths & Limitations
Strengths: Mechanistically well-motivated (targets a specific, measurable pathophysiological pathway — CFH-mediated oxidative injury); prespecified biomarker subgroup analysis; NIH/PETAL Network rigor.
Limitations: Primary endpoint not met in the overall population; phase 2b size limits power for mortality; CFH-high subgroup benefit, while prespecified, requires phase 3 confirmation before practice change.
8. Interpretation & Practice Impact
Does not support routine acetaminophen for organ-dysfunction prevention in unselected sepsis, but the CFH-high subgroup signal (less ventilation need, favorable mortality trend) supports pursuing a phase 3 trial specifically enriched for elevated cell-free hemoglobin.
9. Controversies & Subsequent Evidence
NIH and UCSF press coverage frame this as "promising" specifically for the sickest, CFH-high patients, while explicitly noting no overall mortality benefit — an important, balanced framing distinguishing a mechanistically-targeted subgroup signal from a general practice recommendation. A subsequent retrospective propensity-score analysis (Obeidalla et al., CHEST Critical Care 2025) further explored acetaminophen and clinical outcomes in sepsis using the related Ibuprofen in Sepsis Study dataset.
10. Summary & Executive Takeaway
Summary: ASTER, a phase 2b PETAL Network trial, randomized ~447-488 US ICU patients with sepsis and organ dysfunction to IV acetaminophen or placebo for 5 days. The primary outcome (organ-support-free days to day 28) was not significantly improved overall, but a prespecified high-cell-free-hemoglobin subgroup showed the greatest benefit (less ventilation, favorable mortality trend).
Overall Takeaway: Acetaminophen does not improve organ-support-free days in unselected sepsis, but a biomarker-defined (high CFH) subgroup shows a promising signal warranting phase 3 confirmation — illustrating a precision-medicine approach to an otherwise simple, cheap intervention.
11. Bibliography
- Obeidalla SN, Bernard GR, Ware LB, Kerchberger VE. Acetaminophen and Clinical Outcomes in Sepsis: Retrospective Propensity Score Analysis. CHEST Crit Care. 2025;3(1):100118.